Determinants of outcome following PSMA-based radioligand therapy and mechanisms of resistance in patients with metastatic castration-resistant prostate cancer

[(177)Lu]Lu-PSMA has recently been approved for use in the post-taxane, post-novel hormonal-agent setting in patients with metastatic castration-resistant prostate cancer. As a beta-emitting radioligand targeting prostate-specific membrane antigen (PSMA), it delivers radiation to cells expressing PS...

Descripción completa

Detalles Bibliográficos
Autores principales: Kostos, Louise, Buteau, James P., Hofman, Michael S., Azad, Arun A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Advancing and Innovating in the Era of PSMA theranostics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10262652/
https://www.ncbi.nlm.nih.gov/pubmed/37323184
http://dx.doi.org/10.1177/17588359231179309

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10262652/
https://www.ncbi.nlm.nih.gov/pubmed/37323184
http://dx.doi.org/10.1177/17588359231179309

Ejemplares similares